Show simple item record

dc.contributor.authorGupta, V.
dc.contributor.authorKremyanskaya, M.
dc.contributor.authorMascarenhas, J.
dc.contributor.authorPalandri, F.
dc.contributor.authorPatriarca, A.
dc.contributor.authorDevos, T.
dc.contributor.authorHarrison, C.
dc.contributor.authorPassamonti, F.
dc.contributor.authorRampal, R.
dc.contributor.authorMead, A.
dc.contributor.authorScandura, J.
dc.contributor.authorHobbs, G.
dc.contributor.authorTalpaz, M.
dc.contributor.authorGranacher, N.
dc.contributor.authorSomervaille, Tim CP
dc.contributor.authorHoffman, R.
dc.contributor.authorBose, P.
dc.contributor.authorColak, G.
dc.contributor.authorShao, J.
dc.contributor.authorCui, J. K.
dc.contributor.authorBobba, S.
dc.contributor.authorLuptakova, K.
dc.contributor.authorVerstovsek, S.
dc.date.accessioned2021-09-30T11:56:13Z
dc.date.available2021-09-30T11:56:13Z
dc.date.issued2021en
dc.identifier.citationGupta V, Kremyanskaya M, Mascarenhas J, Palandri F, Patriarca A, Devos T, et al. Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study. Clinical Lymphoma Myeloma & Leukemia. 2021;21:S362-S.en
dc.identifier.urihttp://hdl.handle.net/10541/624645
dc.description.abstractContext: Pelabresib (CPI-0610), a fi rst-in-class, oral, small molecule inhibitor of BET proteins (BETi), has potential to promote disease-modifying activity through altered gene regulation of key oncogenic, fi brotic, and infl ammatory factors in MF. Treatment with JAKi ruxolitinib (rux) or fedratinib in the frontline setting is associated with approximately 30–40% splenic response (spleen volume reduction 35% [SVR35]) at 6 months. BETi pelabresib monotherapy demonstrated clinical activity in heavily pre-treated MF pts. Therefore, combination of pelabresib with rux is expected to achieve higher SVR35 response rate in JAKi treatment-naïve MF pts. Objective: Evaluation of pelabresib in combination with rux in JAKi treatment-naïve MF pts. Design: Pts with MF who were not previously treated with JAKi were enrolled in Arm 3 of MANIFEST. The primary endpoint is SVR35 response at wk 24. Pts were treated with pelabresib 125 mg daily on days 1–14 in a 21-day cycle in combination with rux, which was dosed based on the baseline platelet count. Results: As of 29 September 2020, 78 pts were treated, and 66 pts were ongoing. Baseline characteristics were mean age: 67 years; 72% male; primary MF: 54% pts; DIPSS Int-2: 76% pts; IPSS Int-2: 83%; Hgb <10g/dL: 65%; median platelet: 294 x 109 /L (range: 100, 1849); median spleen volume: 1719 cc (range: 451, 4782); median TSS: 16 (range: 0, 38); high molecular-risk mutations: 55%, JAK2 mutation: 72%. At wk 24, 67% (42/63) pts achieved SVR35 (median % change from baseline: -50%; range: -84.4%, 23.7%). Subgroup analysis showed that mean percentage change in spleen volume at wk 24 was consistent across subgroups based on gender, age, risk score, MF subtype, baseline platelet count, and baseline spleen size. Importantly, subgroup analysis based on molecular fi ndings showed a signifi cant benefi t regardless of the mutational status, including the presence of ASXL1 mutation, which generally carries a poor prognosis. Pelabresib was generally well tolerated. Conclusions: Pelabresib treatment in combination with rux in JAKi treatment-naïve MF pts resulted in spleen volume reduction that was greater than what would be expected with rux alone, regardless of baseline patient disease and demographic characteristicsen
dc.language.isoenen
dc.titleClinical benefit of pelabresib (Cpi-0610) in combination with ruxolitinib in JAK inhibitor treatment-naive myelofibrosis patients: interim efficacy subgroup analysis from Arm 3 of the MANIFEST Phase 2 Studyen
dc.typeOtheren
dc.contributor.departmentPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canadaen
dc.identifier.journalClinical Lymphoma Myeloma & Leukemiaen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record